Entera Bio Ltd.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $147.9M
- Price
- $3.23
- % Change (Daily % change from the live per-ticker quote feed.)
- -1.22%
- Volume
- 441.3K
About
Entera Bio Ltd. is a biopharmaceutical firm in the clinical development phase, dedicated to creating and marketing oral medications composed of large molecules, addressing medical conditions that currently lack adequate treatments. Its primary experimental drugs are EB612, currently undergoing Phase II clinical assessment for hypoparathyroidism, and EB613, which has concluded Phase II studies for osteoporosis and is now in Phase I trials for treating non-healing bone fractures. Furthermore, the company holds a collaborative research and licensing pact with Amgen Inc. aimed at identifying and advancing potential therapeutic compounds for inflammatory conditions and other grave ailments. Established in 2009, Entera Bio Ltd. operates from its headquarters in Jerusalem, Israel.
Quick stats
Shares outstanding49.3M
Computed float38.0M
Float / shares77.1%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001638097
Websitehttps://www.enterabio.com
AI Summary
AI-generated1/22
standardbullishexecutive change
Entera Appoints Global Pharmaceutical Leader Riccardo Paolo Camisasca, M.D., as Chief Medical Officer Ahead of Planned EB613 Phase 3 Initiation
Entera Bio appointed Dr. Riccardo Paolo Camisasca as Chief Medical Officer, bringing over 30 years of global pharmaceutical experience from companies including Sumitomo Pharma, Takeda, and Novartis.
The strategic hire strengthens the clinical leadership team as the company prepares for the planned Phase 3 initiation of EB613, its lead oral treatment for osteoporosis.
Management highlighted Dr. Camisasca's expertise in late-stage development and regulatory strategy as critical for advancing the broader oral peptide pipeline.